MCID: VRL003
MIFTS: 52

Variola Major

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Variola Major

MalaCards integrated aliases for Variola Major:

Name: Variola Major 12 15 74
Smallpox 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050508
ICD9CM 36 050.0
SNOMED-CT 69 47452006

Summaries for Variola Major

Disease Ontology : 12 A smallpox that results in severe infection, located in skin, has material basis in Variola virus. The infection results in_formation_of lesions.

MalaCards based summary : Variola Major, also known as smallpox, is related to smallpox and variola minor, and has symptoms including fever, pruritus and exanthema. An important gene associated with Variola Major is TLR3 (Toll Like Receptor 3), and among its related pathways/superpathways are Akt Signaling and IL-2 Pathway. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and testes, and related phenotypes are neoplasm and respiratory system

Wikipedia : 77 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Variola Major

Diseases related to Variola Major via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 smallpox 32.5 IFNG IL2
2 variola minor 11.6
3 hand, foot and mouth disease 10.2 IFNG TLR3
4 vaccinia 10.2
5 campylobacteriosis 10.2 IFNG TLR4
6 myositis fibrosa 10.2 IFNG TLR4
7 hepatitis e 10.2 IFNG TLR3
8 allergic conjunctivitis 10.1 IFNG TLR3
9 invasive aspergillosis 10.1 IFNG TLR4
10 aspergillosis 10.1 IFNG TLR4
11 q fever 10.1 IFNG TLR4
12 dengue hemorrhagic fever 10.1 IFNG TLR3
13 echinococcosis 10.1 IFNG TLR4
14 orofacial granulomatosis 10.1 CCL3 IFNG
15 melioidosis 10.1 IFNG TLR4
16 typhoid fever 10.1 IFNG TLR4
17 boutonneuse fever 10.1 IL2 TLR4
18 salmonellosis 10.1 IFNG TLR4
19 fixed drug eruption 10.1 IFNG IL2
20 berylliosis 10.1 IFNG IL2
21 atopic keratoconjunctivitis 10.1 IFNG IL2
22 keratoconjunctivitis 10.1 IFNG IL2
23 conjunctivitis 10.1 IFNG IL2
24 cutaneous leishmaniasis 10.1 IFNG TLR4
25 clonorchiasis 10.1 IFNG IL2
26 crohn's colitis 10.1 IFNG IL2
27 chronic active epstein-barr virus infection 10.1 IFNG IL2
28 intermediate uveitis 10.1 IFNG IL2
29 lymphadenitis 10.1 IFNG TLR4
30 posterior uveitis 10.1 IFNG IL2
31 erythema multiforme 10.0 IFNG IL2
32 coccidiosis 10.0 IFNG IL2
33 hematopoietic stem cell transplantation 10.0 IFNG IL2
34 vernal conjunctivitis 10.0 IFNG IL2
35 stevens-johnson syndrome/toxic epidermal necrolysis 10.0 IFNG IL2
36 autoimmune disease of endocrine system 10.0 IFNG IL2
37 chlamydia 10.0 IFNG TLR4
38 hypersensitivity reaction type iv disease 10.0 IFNG IL2
39 leprosy 3 10.0 IFNG IL2
40 acute graft versus host disease 10.0 IFNG IL2
41 lepromatous leprosy 10.0 IFNG IL2
42 toxoplasmosis 10.0 IFNG TLR4
43 autoimmune uveitis 10.0 IFNG IL2
44 testicular disease 10.0 IFNG IL2
45 pleurisy 10.0 IFNG IL2
46 cowpox 10.0
47 herpes zoster 10.0 IFNG IL2
48 tropical spastic paraparesis 10.0 IFNG IL2
49 tonsillitis 10.0 IFNG IL2
50 mumps 10.0 IFNG IL2

Graphical network of the top 20 diseases related to Variola Major:



Diseases related to Variola Major

Symptoms & Phenotypes for Variola Major

UMLS symptoms related to Variola Major:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Variola Major:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.26 IFNG IL2 TLR3 TLR4
2 respiratory system MP:0005388 8.92 IFNG IL2 TLR3 TLR4

Drugs & Therapeutics for Variola Major

Drugs for Variola Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
4 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1
6 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1
7 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
8 Iron-Dextran Complex Phase 3
9
Phenol Approved, Experimental Phase 2 108-95-2 996
10
tannic acid Approved Phase 1, Phase 2 1401-55-4
11
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
12 Immunoglobulin G Phase 2,Phase 1
13
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453
14 Pharmaceutical Solutions Phase 1
15 diuretics Phase 1
16 Natriuretic Agents Phase 1
17 polysaccharide-K Phase 1
18 Protective Agents Phase 1
19 Radiation-Protective Agents Phase 1
20 Anti-Infective Agents Phase 1
21 interferons Phase 1
22 Anti-Bacterial Agents Phase 1
23 Antiviral Agents Phase 1
24 Interferon Inducers Phase 1
25 Adjuvants, Immunologic Phase 1
26 Antibiotics, Antitubercular Phase 1
27 Keyhole-limpet hemocyanin Phase 1
28 Liver Extracts Phase 1
29 Laxatives Phase 1
30 Poly I-C Phase 1
31 Gastrointestinal Agents Phase 1
32 Poly ICLC Phase 1
33 Carboxymethylcellulose Sodium Phase 1
34 Cathartics Phase 1
35 Interferon-gamma

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
2 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
3 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
4 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
5 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
6 Safety and Efficacy of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
7 A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat Completed NCT02474589 Phase 3 tecovirimat
8 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV Completed NCT01158157 Phase 3
9 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
10 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
11 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Not yet recruiting NCT03699124 Phase 3
12 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
13 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
14 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
15 Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults Completed NCT00053482 Phase 2
16 Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
17 Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Completed NCT00258947 Phase 2
18 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
19 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
20 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
21 A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
22 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
23 Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. Completed NCT00189956 Phase 2
24 Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® Completed NCT01827371 Phase 2
25 A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects Completed NCT00316524 Phase 2
26 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
27 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
28 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2
29 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
30 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
31 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients Completed NCT00316589 Phase 2
32 A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis Completed NCT00316602 Phase 2
33 Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients Completed NCT00189904 Phase 1, Phase 2
34 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
35 Dryvax Dilution-Prev Vacc Adults Completed NCT00032708 Phase 2
36 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
37 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
38 Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
39 A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites Completed NCT00890760 Phase 1, Phase 2
40 PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
41 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
42 EMaBS TB Vaccine Study Not yet recruiting NCT03681860 Phase 1, Phase 2
43 Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Terminated NCT00053508 Phase 2
44 Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults Completed NCT00079820 Phase 1
45 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® Completed NCT00042094 Phase 1
46 Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects Completed NCT00189969 Phase 1
47 Human Immune Responses Smallpox Completed NCT00068198 Phase 1
48 Safety and Immunogenicity of CJ-50300 Completed NCT00336635 Phase 1
49 Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects Completed NCT00565929 Phase 1 Placebo
50 A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers Completed NCT00002261 Phase 1

Search NIH Clinical Center for Variola Major

Genetic Tests for Variola Major

Anatomical Context for Variola Major

The Foundational Model of Anatomy Ontology organs/tissues related to Variola Major:

20
Skin

MalaCards organs/tissues related to Variola Major:

42
Skin, Testes, T Cells, Eye, Kidney, Tonsil, B Cells

Publications for Variola Major

Articles related to Variola Major:

(show top 50) (show all 3016)
# Title Authors Year
1
Atypical Cowpox Virus Infection in Smallpox-Vaccinated Patient, France. ( 30666929 )
2019
2
Preemptive Tecovirimat Use in an Active Duty Member Presenting with Acute Myeloid Leukemia after Smallpox Vaccination. ( 30959520 )
2019
3
Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. ( 30453097 )
2019
4
A Case Series of Smallpox Vaccination-Associated Myopericarditis: Effects on Safety and Readiness of the Active Duty Soldier. ( 29947793 )
2019
5
Smallpox Autoinoculation Via Tattoo in a Soldier. ( 30085282 )
2019
6
Recurrent epicardial ventricular tachycardia following smallpox vaccination. ( 30693196 )
2019
7
Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox. ( 30853252 )
2019
8
Edward Jenner's 1798 report of challenge experiments demonstrating the protective effects of cowpox against smallpox. ( 29978749 )
2018
9
Myocarditis secondary to smallpox vaccination. ( 29572367 )
2018
10
Revisiting Jenner's mysteries, the role of the Beaugency lymph in the evolutionary path of ancient smallpox vaccines. ( 28827144 )
2018
11
Does smallpox vaccination modify HIV disease progression among ART-naive people living with HIV in Africa? ( 29235428 )
2018
12
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. ( 29300297 )
2018
13
Challenges and Achievements in Prevention and Treatment of Smallpox. ( 29382130 )
2018
14
How Valid Are Assumptions About Re-emerging Smallpox? A Systematic Review of Parameters Used in Smallpox Mathematical Models. ( 29425329 )
2018
15
Post-Smallpox Vaccination Skin Eruption in a Marine. ( 29546340 )
2018
16
Influence of Population Immunosuppression and Past Vaccination on Smallpox Reemergence. ( 29553311 )
2018
17
Smallpox vaccine complications: the dermatologist's role in diagnosis and management. ( 29554163 )
2018
18
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. ( 29652929 )
2018
19
The geography of smallpox in England before vaccination: A conundrum resolved. ( 29684651 )
2018
20
Oral Tecovirimat for the Treatment of Smallpox. ( 29972742 )
2018
21
Never Mind the Science, Here's the Convention on Biological Diversity: Viral Sovereignty in the Smallpox Destruction Debate. ( 29978646 )
2018
22
Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccine. ( 30048524 )
2018
23
An antiviral for smallpox. ( 30082865 )
2018
24
Bayesian Phylogeography and Pathogenic Characterization of Smallpox Based on HA, ATI, and CrmB Genes. ( 30099520 )
2018
25
The spectre of smallpox lingers. ( 30104592 )
2018
26
First Smallpox Drug Approved. ( 30140861 )
2018
27
Smallpox antiviral ends decades-long search. ( 30188546 )
2018
28
Drug Approved to Treat Smallpox After a Bioterrorist Attack. ( 30358593 )
2018
29
Long-term effects of smallpox vaccination on expression of the HIV-1 co-receptor CCR5 in women. ( 30440008 )
2018
30
Oral Tecovirimat for the Treatment of Smallpox. ( 30462945 )
2018
31
Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox - Part II. ( 30488769 )
2018
32
The last case of smallpox. ( 30507458 )
2018
33
Equination (inoculation of horsepox): An early alternative to vaccination (inoculation of cowpox) and the potential role of horsepox virus in the origin of the smallpox vaccine. ( 29137821 )
2017
34
A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox. ( 28003603 )
2017
35
Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research. ( 29231870 )
2017
36
Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. ( 27380797 )
2017
37
Formulation and Characterization of a Ternary Inclusion Complex Containing Hydroxypropyl-β-cyclodextrin and Meglumine for Solubility Enhancement of Poorly Water-Soluble ST-246, an Anti-Smallpox Drug. ( 27697036 )
2017
38
Estimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine. ( 27739111 )
2017
39
Modelling and Bayesian analysis of the Abakaliki smallpox data. ( 28038869 )
2017
40
Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox. ( 28039021 )
2017
41
Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. ( 28046039 )
2017
42
Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. ( 28093339 )
2017
43
Donald Ainslie (D.A.) Henderson, M.D., M.P.H. (1928 - 2016) Smallpox Eradication: Leadership and Legacy. ( 28170040 )
2017
44
Viral Evolution: Mummy Virus Challenges Presumed History of Smallpox. ( 28171759 )
2017
45
George Boole, saucy little Alice and an uneventful smallpox vaccination: one of the greatest stories never told. ( 28235836 )
2017
46
The Peace Gun and the Eradication of Smallpox. ( 28290922 )
2017
47
Treacle and Smallpox: Two Tests for Multicriteria Decision Analysis Models in Health Technology Assessment. ( 28292498 )
2017
48
Variola minor in coalfield areas of England and Wales, 1921-34: Geographical determinants of a national smallpox epidemic that spread out of effective control. ( 28351006 )
2017
49
Relocating Pastorian Medicine: Accommodation and Acclimatization of Pastorian Practices against Smallpox at the Pasteur Institute of Chengdu, China, 1908-1927. ( 28397646 )
2017
50
Al Rhazes and the Beginning of the End of Smallpox. ( 28492840 )
2017

Variations for Variola Major

Expression for Variola Major

Search GEO for disease gene expression data for Variola Major.

Pathways for Variola Major

Pathways related to Variola Major according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 CCL3 IL2 TLR3 TLR4
2
Show member pathways
12.87 IFNG IL2 TLR3 TLR4
3
Show member pathways
12.49 IFNG TLR3 TLR4
4
Show member pathways
12.43 IL2 TLR3 TLR4
5
Show member pathways
12.31 IFNG IL2 TLR4
6
Show member pathways
12.29 CCL3 IFNG IL2 TLR3 TLR4
7 12.27 IFNG IL2 TLR3
8
Show member pathways
12.02 IFNG TLR3 TLR4
9
Show member pathways
11.91 IFNG TLR3 TLR4
10 11.87 IFNG TLR3 TLR4
11
Show member pathways
11.81 CCL3 IFNG IL2
12
Show member pathways
11.73 IL2 TLR3 TLR4
13 11.69 IFNG IL2 TLR4
14
Show member pathways
11.63 CCL3 IFNG IL2
15 11.6 TLR3 TLR4
16 11.58 IFNG IL2
17
Show member pathways
11.54 IFNG IL2
18 11.53 IFNG IL2
19 11.5 CCL3 IFNG TLR4
20 11.47 IFNG IL2
21
Show member pathways
11.44 IFNG IL2
22 11.43 CCL3 IFNG TLR4
23
Show member pathways
11.42 IFNG IL2
24 11.34 IFNG IL2
25 11.34 CCL3 IFNG IL2
26 11.31 IFNG TLR4
27 11.29 IFNG IL2
28 11.29 IFNG TLR4
29 11.26 IFNG IL2
30 11.18 CCL3 IFNG IL2
31 11.09 IFNG IL2
32
Show member pathways
11.04 IFNG IL2 TLR3 TLR4
33 11.02 IFNG IL2
34 10.98 IFNG IL2
35 10.94 IFNG IL2
36 10.89 TLR3 TLR4

GO Terms for Variola Major

Biological processes related to Variola Major according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.83 CCL3 IFNG IL2
2 inflammatory response GO:0006954 9.81 CCL3 TLR3 TLR4
3 immune response GO:0006955 9.78 CCL3 IFNG IL2 TLR4
4 positive regulation of gene expression GO:0010628 9.71 CCL3 IFNG TLR3 TLR4
5 positive regulation of JNK cascade GO:0046330 9.67 TLR3 TLR4
6 cellular response to mechanical stimulus GO:0071260 9.66 TLR3 TLR4
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.66 IFNG IL2
8 apoptotic signaling pathway GO:0097190 9.65 TLR3 TLR4
9 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 TLR3 TLR4
10 positive regulation of interleukin-6 production GO:0032755 9.64 TLR3 TLR4
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.64 TLR3 TLR4
12 extrinsic apoptotic signaling pathway GO:0097191 9.63 IFNG TLR3
13 positive regulation of interferon-gamma production GO:0032729 9.62 IL2 TLR4
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 IFNG TLR4
15 positive regulation of B cell proliferation GO:0030890 9.61 IL2 TLR4
16 toll-like receptor signaling pathway GO:0002224 9.61 TLR3 TLR4
17 cellular response to interferon-gamma GO:0071346 9.61 CCL3 TLR3 TLR4
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.6 CCL3 TLR4
19 positive regulation of interleukin-1 beta secretion GO:0050718 9.59 CCL3 TLR4
20 positive regulation of interleukin-8 production GO:0032757 9.58 TLR3 TLR4
21 positive regulation of interferon-beta production GO:0032728 9.58 TLR3 TLR4
22 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.57 TLR3 TLR4
23 positive regulation of chemokine production GO:0032722 9.56 TLR3 TLR4
24 necroptotic process GO:0070266 9.55 TLR3 TLR4
25 regulation of regulatory T cell differentiation GO:0045589 9.54 IFNG IL2
26 I-kappaB phosphorylation GO:0007252 9.52 TLR3 TLR4
27 negative regulation of interleukin-17 production GO:0032700 9.51 IFNG TLR4
28 positive regulation of tumor necrosis factor production GO:0032760 9.5 CCL3 TLR3 TLR4
29 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.49 TLR3 TLR4
30 positive regulation of interferon-beta biosynthetic process GO:0045359 9.46 TLR3 TLR4
31 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.37 TLR3 TLR4
32 positive regulation of interleukin-12 production GO:0032735 9.33 IFNG TLR3 TLR4
33 regulation of dendritic cell cytokine production GO:0002730 9.26 TLR3 TLR4
34 negative regulation of osteoclast differentiation GO:0045671 9.13 CCL3 TLR3 TLR4
35 positive regulation of inflammatory response GO:0050729 8.92 CCL3 IL2 TLR3 TLR4

Molecular functions related to Variola Major according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL3 IFNG IL2

Sources for Variola Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....